Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

On 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then the New England Journal of Medicine, retracted studies that were based on inaccessible data. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. MORU researchers played a key role in bringing this scandal to light, whose consequences continue to play out.

Composite image of many hydroxychloroquine articles

Similar stories

Real-time genetic surveillance can support timely, evidence-based responses to shifting malaria threats

A sharp decline in piperaquine-resistant strains of P. Falciparum malaria following drug policy revisions across the Greater Mekong Subregion (GMS) highlights how real-time genetic data can support timely, evidence-based responses to shifting malaria threats, say researchers in a study published in Nature Communications.